Atomoxetine is a second-line medication treatment option for ADHD

  title={Atomoxetine is a second-line medication treatment option for ADHD},
  author={J. Ghuman and Shari L. Hutchison},
  journal={Evidence-Based Mental Health},
  pages={108 - 108}
Atomoxetine is a non-stimulant that has no abusive potential and a presynaptic inhibitor of the norepinephrine transporter, and has been found to be a safe and effective treatment for attention deficit/hyperactivity disorder (ADHD) in children, adolescents and adults.1 
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments
The efficacy of ATX seems to be lower than CLON, GXR, LDX and MPH, and BUP has the highest incidence rate of withdrawals and the second highest probability of causing adverse effects as well as lack of efficacy; therefore it should not be recommended as a treatment for ADHD. Expand
ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.
A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood. Expand
Lifetime evolution of ADHD treatment
A naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan finds stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected. Expand


Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
  • S. Schwartz, C. Correll
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2014
Short-term ATX treatment is safe and superior to placebo for overall ADHD symptoms and key secondary outcomes, with a medium ES, however, a relevant patient subgroup continues to have significant symptomatology, requiring additional clinical attention. Expand
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies
Important aspects of evaluation and assessment are reviewed and first-line pharmacological treatments are discussed and as well as when to consider using alternative pharmacological agents are discussed. Expand
Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
In preschoolers with ADHD, the presence of no or one co-morbid disorder (primarily oppositional defiant disorder) predicted a large treatment response at the same level as has been found in school-aged children, and two co- Morbid disorders predicted moderate treatment response. Expand
Which treatment for whom for ADHD? Moderators of treatment response in the MTA.
Examination of outcome predictors and moderators in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder found parental depressive symptoms and severity of child ADHD were associated with decreased rates of excellent response; when these 2 characteristics were present, below-average child IQ was an additional moderator. Expand
Comorbid oppositional defiant disorder (ODD), conduct disorder (CD), anxiety and/or depression were allowed. Intervention Atomoxetine monotherapy vs placebo